[go: up one dir, main page]

MX2015000760A - Sistema de suministro de farmaco gastro - retentivo. - Google Patents

Sistema de suministro de farmaco gastro - retentivo.

Info

Publication number
MX2015000760A
MX2015000760A MX2015000760A MX2015000760A MX2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A MX 2015000760 A MX2015000760 A MX 2015000760A
Authority
MX
Mexico
Prior art keywords
drug delivery
delivery systems
floating
floating drug
fdds
Prior art date
Application number
MX2015000760A
Other languages
English (en)
Inventor
Hendrik Jan Cornelis Meijerink
Lekhram Changoer
Anko Cornelus Eissens
Henderik Willem Frijlink
Willem Blom
Marinella Regina Visser
Original Assignee
Apet Holding B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/NL2012/050511 external-priority patent/WO2013009186A1/en
Application filed by Apet Holding B V filed Critical Apet Holding B V
Publication of MX2015000760A publication Critical patent/MX2015000760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a sistemas de suministro de fármaco flotantes (FDDS, por sus siglas en inglés) que proporcionan soluciones a los problemas particulares encontrados a menudo con sistemas de suministro de fármaco flotantes descritos en el campo. Tal problema generalmente reconocido es la vulnerabilidad de los sistemas, especialmente el daño al compartimiento llenado con gas que lo hace inaccesible al agua para impartir su capacidad para flotar, finalmente resultando en un tiempo de residencia gástrica insuficiente. La invención, en un aspecto, proporciona un FDDS auto-reparable que mantiene su capacidad de flotación después de dañarse. Los sistemas de suministro de fármaco flotantes de la invención, adicionalmente, permiten la incorporación de cargas altas de ingredientes activos. Los sistemas de suministro de fármaco flotantes pueden diseñarse de tal manera que la liberación del ingrediente activo desde el sistema ocurre completamente independiente del pH del fluido que rodea el sistema. Adicionalmente, el procedimiento de fabricación del sistema de suministro de fármaco flotante de la invención es sencillo y directo, y por lo tanto económicamente atractivo.
MX2015000760A 2012-07-16 2013-07-15 Sistema de suministro de farmaco gastro - retentivo. MX2015000760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL2012/050511 WO2013009186A1 (en) 2011-07-14 2012-07-16 Nicotinamide compositions and the therapeutic use thereof
PCT/NL2013/050538 WO2014014348A1 (en) 2012-07-16 2013-07-15 Gastro-retentive drug delivery system

Publications (1)

Publication Number Publication Date
MX2015000760A true MX2015000760A (es) 2015-09-10

Family

ID=49162197

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000760A MX2015000760A (es) 2012-07-16 2013-07-15 Sistema de suministro de farmaco gastro - retentivo.

Country Status (6)

Country Link
US (1) US20230115025A1 (es)
EP (1) EP2872140A1 (es)
AU (2) AU2013290875A1 (es)
CA (2) CA3149459A1 (es)
MX (1) MX2015000760A (es)
WO (1) WO2014014348A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016028957B1 (pt) 2014-06-11 2021-12-14 The Brigham And Women's Hospital, Inc. Estrutura de residência gástrica
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
WO2016178971A1 (en) 2015-05-01 2016-11-10 Massachusetts Institute Of Technology Triggerable shape memory induction devices
AU2016342374B2 (en) 2015-10-23 2022-08-04 Nortiva Bio, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
SG11201804384UA (en) 2015-12-08 2018-06-28 Lyndra Inc Geometric configurations for gastric residence systems
US12109305B2 (en) 2016-05-27 2024-10-08 Lyndra Therapeutics, Inc. Materials architecture for gastric residence systems
EP3518902A4 (en) 2016-09-30 2020-07-08 Lyndra, Inc. GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
CA3139217A1 (en) 2019-05-14 2020-11-19 Clexio Biosciences Ltd. Treatment of nocturnal symptoms and morning akinesia in subjects with parkinson's disease
US20230009115A1 (en) * 2020-03-02 2023-01-12 Craft Health Pte Ltd Oral dosage forms for extended drug release
CN112245399B (zh) * 2020-10-29 2023-02-28 西南医科大学 一种二氢杨梅素胃漂浮丸剂及其制备方法
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions
WO2023166225A1 (en) * 2022-03-04 2023-09-07 APET Holding B.V. Digestive enzyme formulations
EP4486301A1 (en) * 2022-03-04 2025-01-08 APeT Holding B.V. Gastroretentive formulations containing protein or peptide
WO2023203008A1 (en) * 2022-04-21 2023-10-26 Conaris Research Institute Ag Oral composition comprising nicotinamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5512411B2 (es) * 1974-03-12 1980-04-02
JPH082781B2 (ja) * 1988-10-18 1996-01-17 嘉明 川島 中空顆粒状医薬及びその製法
WO2010020098A1 (zh) * 2008-08-18 2010-02-25 北京天衡药物研究院 胃滞留药物释出系统及其制备方法和用途
CA2841731A1 (en) * 2011-07-14 2013-01-17 Hendrik Jan Cornelis Meijerink Nicotinamide compositions and the therapeutic use thereof

Also Published As

Publication number Publication date
CA2879282A1 (en) 2014-01-23
EP2872140A1 (en) 2015-05-20
CA2879282C (en) 2022-05-03
CA3149459A1 (en) 2014-01-23
AU2013290875A1 (en) 2015-02-05
WO2014014348A1 (en) 2014-01-23
US20230115025A1 (en) 2023-04-13
AU2018202652A1 (en) 2018-05-10

Similar Documents

Publication Publication Date Title
MX2015000760A (es) Sistema de suministro de farmaco gastro - retentivo.
WO2013188819A3 (en) Mucoadhesive devices for delivery of active agents
GB2499739A (en) Plug and method of unplugging a seat
WO2013179137A3 (en) Systems, methods and devices for embolic protection
EP3273079A4 (en) Electromagnetically enabled active type dynamic gas bearing
EP3441468A3 (en) Delivery methods and compositions for nuclease-mediated genome engineering
MX2013002146A (es) Formulaciones farmaceuticas que utilizan antioxidantes solubles en agua.
MX2013014422A (es) Miembros y métodos de contacto de heridas.
AR088379A1 (es) Formulaciones de etanercept estabilizadas con iones metalicos
WO2013173789A3 (en) Antisense oligonucleotide compositions
FR2943990B1 (fr) Harpon d'ancrage notamment d'un aeronef et systeme d'ancrage comportant un tel harpon.
WO2013006517A3 (en) Method and apparatus for configurable thermal management
FR2943988B1 (fr) Harpon d'ancrage par exemple d'un aeronef et systeme d'ancrage comportant un tel harpon.
IN2014DN07483A (es)
MX344324B (es) Endoprotesis que contiene un recubrimiento de substancia activa.
MX2014016121A (es) Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular.
WO2010118237A3 (en) Techniques for processing a substrate
WO2011032896A3 (de) Verkapselung unter verwendung von wachsartigen substanzen
WO2013006558A3 (en) Compositions and methods for treating skeletal myopathy
ECSP12012316A (es) Un sistema de control de estacionamientos a traves de un sistema de un tercero
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
PH12013501210A1 (en) Liquid formulation containing protein and lambda carrageenan from halymeniales
MX2012012978A (es) Metodo para producir pleurodesis.
AR066028A1 (es) Procedimiento para la extraccion de teaflavinas
PH12014502323A1 (en) Oral formulation